Regadenoson

FDA Approved: * April 11, 2022
Pharm Company: * APOTEX INC
Category: Heart (Cardiac)

Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.[1] The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects. Regadenoso... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lexiscan(r) (Regadenoson) .08 mg/ml Intravenous Injection, Solution
NDC: 51662-1448
Labeler:
Hf Acquisition Co LLC, Dba Healthfirst
Regadenoson .08 mg/ml Intravenous Injection
NDC: 55150-443
Labeler:
Eugia Us LLC
Regadenoson .08 mg/ml Intravenous Injection, Solution
NDC: 68083-175
Labeler:
Gland Pharma Limited
Regadenoson .08 mg/ml Intravenous Injection, Solution
NDC: 71288-201
Labeler:
Meitheal Pharmaceuticals Inc.

Related Brands

Drugs with the same active ingredients